Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm
18 oct. 2017 04h22 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Oct. 18, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
12 sept. 2017 08h36 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Announces Second Quarter 2017 Financial Results
03 août 2017 16h05 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
01 août 2017 16h05 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
24 juil. 2017 02h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, July 24, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
27 juin 2017 07h00 HE
|
NeuroDerm Ltd.
-Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients ON by...
NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
08 juin 2017 12h01 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
06 juin 2017 09h05 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
05 juin 2017 12h01 HE
|
NeuroDerm Ltd.
-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the...
NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017
30 mai 2017 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...